In this study, we observed a decrease in pERK and pAKT expression levels in MDS patients categorized as low-middle risk, and high risk patients exhibited an increase in both pERK and pAKT expression levels. This evidence concerns the gene EIF2AK3 and myelodysplastic syndrome.